UNITHROID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Unithroid, and what generic alternatives are available?
Unithroid is a drug marketed by Stevens J and is included in one NDA.
The generic ingredient in UNITHROID is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Unithroid
A generic version of UNITHROID was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
US Patents and Regulatory Information for UNITHROID
Summary
UNITHROID (levothyroxine sodium) is a synthetic thyroid hormone used primarily for hypothyroidism treatment. Its investment potential depends on market size, patent status, competitive landscape, regulatory environment, and manufacturing risks. These factors influence revenue stability, growth prospects, and valuation.
Market Overview
The global hypothyroidism treatment market is expected to reach $2.7 billion by 2027, growing at approximately 3.4% annually (Fortune Business Insights, 2021). Levothyroxine products dominate this market, with UNITHROID holding a significant share in the US due to formulary preferences and established prescribing patterns.
Product and Patent Dynamics
UNITHROID's primary formulation is a generic version of levothyroxine sodium. It faced a patent expiration in 2014 but remains branded through market exclusivity strategies and manufacturing advantages distinct from generics. As a generic, its revenue depends heavily on market penetration, pricing, and physician prescribing behaviors.
Doctor and patient familiarity with UNITHROID supports stable demand. However, regulatory uncertainties surrounding compounding pharmacy limitations and market competition influence its future trajectory. The company that markets UNITHROID has maintained a strong market presence through supply chain reliability and price competitiveness.
Competitive Landscape
The key competitors include other generic levothyroxine brands such as Euthyrox and Synthroid. Brand premiums for Synthroid (AbbVie) persist due to perceived reliability and brand recognition, but generics like UNITHROID offer cost advantage, boosting adoption in value-focused healthcare systems.
Regulatory and Manufacturing Considerations
The FDA enforces strict bioequivalence and manufacturing standards for levothyroxine products. Market shifts include a focus on consistency, particularly following incidents of potency variability in generics. Ensuring high-quality manufacturing helps maintain market position. Supply chain disruptions or quality issues could impact sales and reputation.
Financial and Investment Fundamentals
Revenue estimates for UNITHROID are approximately $300-\$500 million annually (based on market share and pricing). The margins depend on production efficiency, raw material costs, and margin pressure from generic competition.
Profitability remains stable if manufacturing costs are controlled and market share is maintained.
Pricing pressures, particularly from payers and formulary negotiations, can compress margins.
Risks
- Patent and regulatory changes impacting market exclusivity or manufacturing permits.
- Growing competition from new generics and potential biosimilar entries.
- Supply chain disruptions, especially raw material price fluctuations.
- Pricing pressures due to formulary negotiations.
Opportunities
- Expansion into emerging markets where hypothyroidism treatment remains underpenetrated.
- Innovation in delivery or combination therapies, though currently limited for this drug class.
- Strategic partnerships to improve manufacturing scale and quality.
Conclusion
UNITHROID remains a stable cash-generating asset within the hypothyroidism market, primarily driven by consistent demand and brand loyalty. Investment value hinges on maintaining manufacturing quality and navigating competitive and regulatory environments. The drug’s valuation could improve if the manufacturer expands market share or develops innovative formulations but faces downside if patent or quality issues arise.
Key Takeaways
- UNITHROID has a stable revenue base due to the longstanding clinical use of levothyroxine.
- Competition from generics and formulary negotiations influence pricing and margins.
- Regulatory standards heighten manufacturing costs but protect market quality requirements.
- Growth opportunities are limited but exist in emerging markets and potential formulation innovations.
- Risks include patent expirations, market saturation, and supply chain issues.
FAQs
More… ↓
